Seizure reduction with fluoxetine in an adult woman with Dravet syndrome

Epilepsy and Behavior Case Reports

Volumn 2, Issue 1, 2014, Pages 54-56

  Meador, Kimford J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Antidepressant; Dravet syndrome; Epilepsy; Seizures; Selective serotonin reuptake inhibitor; Serotonin

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETIRACETAM; FELBAMATE; FEXOFENADINE; FLUOXETINE; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RETIGABINE; SODIUM CHANNEL NAV1.1; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADULT; AGING; ARTICLE; ATONIC SEIZURE; BRAIN ATROPHY; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; FOCAL EPILEPSY; GENE DELETION; GENERAL ASPECTS OF DISEASE; HUMAN; KETOGENIC DIET; MEDICAL HISTORY; MYOCLONUS SEIZURE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCN1A GENE; SEIZURE REDUCTION; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TONIC CLONIC SEIZURE;

EID: 84898677304     PISSN: 22133232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ebcr.2014.03.001     Document Type: Article

References (23)

1. Dravet C. Les épilepsie grave de l'enfant. Vie Med 1978, 8:543-548.
2. Dravet C., Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol 2013, 111:627-633.
3. Guerrini R. Dravet syndrome: the main issues. Eur J Paediatr Neurol 2012, 16(Suppl. 1):S1-S4.
4. Scheffer I.E., Berkovic S.F. Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. Brain 1997, 120:479-490.
5. Wallace R.H., Scheffer I.E., Barnett S., Richards M., Dibbens L., Desai R.R., et al. Neuronal sodium-channel alpha 1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet 2001, 68:859-865.
6. Singh R., Andermann E., Whitehouse W.P., Harvey A.S., Keene D.L., Seni M.H., et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEF+?. Epilepsia 2001, 42:837-844.
7. Claes L., Del-Favero J., Cuelemans B., Lagae L., Van Broeckhoven C., De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001, 68:1327-1332.
8. Scheffer I.E. Diagnosis and long-term course of Dravet syndrome. Eur J Paediatr Neurol 2012, 16(Suppl. 1):S5-S8.
9. Lossin C. A catalog of SCN1A variants. Brain Dev 2009, 31:114-130.
10. Yu F.H., Mantegazza M., Westenbroek R.E., Robbins C.A., Kalume F., Burton K.A., et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006, 9:1142-1149.
11. Ogiwara I., Miyamoto H., Morita N., Atapour N., Mazaki E., Inoue I., et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007, 27(22):5903-5914.
12. Ceulemans B., Boel M., Leyssens K., Van Rossem C., Neels P., Jorens P.G., et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012, 53(7):1131-1139.
13. Hamid H1., Kanner A.M. Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?. Epilepsy Behav 2013, 26(3):261-265.
14. Richerson G.B., Buchanan G.F. The serotonin axis: shared mechanisms in seizures, depression, and SUDEP. Epilepsia 2011, 52(Suppl. 1):28-38.
15. Bagdy G., Kecskemeti V., Riba P., Jakus R. Serotonin and epilepsy. J Neurochem 2007, 100(4):857-873.
16. Igelstrom K.M. Preclinical antiepileptic actions of selective serotonin reuptake inhibitors - implications for clinical trial design. Epilepsia 2012, 53(4):596-605.
17. Beck S.G., Choi K.C. 5-Hydroxytryptamine hyperpolarizes CA3 hippocampal pyramidal cells through an increase in potassium conductance. Neurosci Lett 1991, 133:93-96.
18. Okuhara D.Y., Beck S.G. 5-HT1A receptor linked to inward-rectifying potassium current in hippocampal CA3 pyramidal cells. J Neurophysiol 1994, 71:2161-2167.
19. Graf M., Jakus R., Kantor S., Levay G., Bagdy G. Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy. Neurosci Lett 2004, 359(1-2):45-48.
20. Hoyer D., Fozard J.R., Hartig P.R. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacol Rev 1994, 46(2):157-203.
21. Favale E., Audenino D., Cocito L., Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 2003, 12(5):316-318.
22. Specchio L.M., Iudice A., Specchio N., La Neve A., Spinelli A., Galli R., et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004, 27(3):133-136.
23. Favale E., Mainardi P., Rubino V., Lunardi G., Albano C. The anticonvulsant effect of fluoxetine in humans. Neurology 1995, 45:1926.